Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

302 IV. SPECIAL POPULATIONSWeiss, R. D., Griffin, M. L., Greenfield, S. F., Najavits, L. M., Wyner, D., Soto, J. A., &Hennen, J. A. (2000). Group therapy for patients with bipolar disorder and substancedependence: Results of a pilot study. J Clin Psychiatry, 61, 361–367.Weiss, R. D., & Hufford, M. R. (1999). Substance abuse and suicide. In D. Jacobs (Ed.),Harvard Medical School guide to assessment and intervention in suicide (pp. 300–310).New York: Simon & Schuster.Weiss, R. D., Mirin, S. M., & Frances, R. J. (1992). The myth of the typical dual diagnosispatient. Hosp Community Psychiatry, 43, 107–108.Weiss, R. D., Najavits, L. M., & Greenfield, S. F. (1999). A relapse prevention groupfor patients with bipolar and substance use disorders. J Subst Abuse Treat, 16, 47–54.Weiss, R. D., Najavits, L. M., Greenfield, S. F., Soto, J. A., Shaw, S. R., & Wyner, D.(1988). Psychopathology in cocaine abusers: Changing trends. J Nerv Ment Dis,176, 719–725.Wilens, T. E. (2001, Fall). Does the medicating of ADHD increase or decrease the riskfor later substance abuse? An evaluation of the literature [Insert]. Am Assoc AddictPsychiatry News, pp. 1–4.Wilens, T. E., Biederman, J., Prince, J., Spencer, T. J., Faraone, S. V., Warburton, R., etal. (1996). Six-week, double-blind, placebo-controlled study of desipramine foradult attention deficit hyperactivity disorder. Am J Psychiatry, 153, 1147–1153.Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., et al.(2002). A controlled clinical trial of bupropion for attention deficit hyperactivitydisorder in adults. Am J Psychiatry, 158, 282–288.Woodward, B., Fortgang, J., Sullivan-Trainor, M., Stojanov, H., & Mirin, S. M. (1991).Underdiagnosis of alcohol dependence in psychiatric inpatients. Am J Drug AlcoholAbuse, 17, 373–388.Ziedonis, D., Richardson, T., Lee, E., Petrakis, I., & Kosten, T. (1992). Adjunctivedesipramine in the treatment of cocaine abusing schizophrenics. PsychopharmacolBull, 28, 309–314.Ziedonis, D., & Trudeau, K. (1997). Motivation to quit using substances among individualswith schizophrenia: Implications for a motivation-based treatment model.Schizophr Bull, 23, 229–238.Ziedonis, D., Williams, J., Corrigan, P., & Smelsen, D. A. (2000). Management of substanceabuse in schizophrenia. Psychiatr Ann, 30, 67–75.Zimmet, S. V., Strous, R. D., Burgess, E. S., Kohnstamm, S., & Green, A. I. (2000).Effect of clozapine on substance use in patients with schizophrenia and schizoaffectivedisorder: A retrospective study. J Clin Psychopharmacol, 20, 94–98.